Want to see IN:GUJTHEM full AI Analyst Report?
GUJTHEM Stock Chart & Stats
₹432.00
--
Market closed
₹432.00
--
Day’s Range― - ―
52-Week Range₹225.75 - ₹479.45
Previous CloseN/A
VolumeN/A
Average Volume (3M)12.26K
Market Cap
₹45.71B
Enterprise Value₹43.88K
Total Cash (Recent Filing)₹103.83M
Total Debt (Recent Filing)₹714.92M
Price to Earnings (P/E)92.4
Beta2.00
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)2.41
Shares Outstanding108,965,260
10 Day Avg. Volume22,565
30 Day Avg. Volume12,264
Financial Highlights & Ratios
PEG Ratio-11.90
Price to Book (P/B)8.62
Price to Sales (P/S)14.96
P/FCF Ratio-19.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.9
Revenue Forecast (FY)₹1.88B
Bulls Say, Bears Say
Bulls Say
B2B API Manufacturing PlatformAPI and intermediate manufacturing supplies inputs to finished-drug producers through domestic and export sales. This B2B position supports recurring industrial demand and gives the company exposure to pharmaceutical production growth, although customer concentration is not provided.
Strong Profitability And Revenue ExpansionRevenue rose about 107% year over year in 2026, while EBIT margin remained about 38% and net margin about 28%. Sustained profitability at this scale can support reinvestment and resilience, even as cost and product-mix trends require monitoring.
Substantial Equity Capital CushionEquity remains sizable relative to assets despite the debt increase, providing a capital cushion for an API manufacturer. This can help absorb operational volatility and fund capacity or working-capital needs, though the cushion is less protective if leverage continues rising.
Bears Say
Sharp Gross-margin CompressionThe steep gross-margin decline indicates weaker cost absorption, pricing, product mix, or input-cost economics. If persistent, it could limit the benefit of strong sales growth and reduce the company’s ability to convert expanding API volumes into durable earnings.
Deteriorating Cash-flow ConversionOperating cash flow covered only about 0.57x net income in 2026, versus 4.43x previously, while free cash flow became deeply negative. Persistent weak conversion would constrain self-funded expansion and increase reliance on financing or working-capital improvements.
Rapid Increase In LeverageThe sharp rise in debt-to-equity increases fixed financial obligations and reduces flexibility if API prices, demand, or margins weaken. Combined with negative free cash flow, higher leverage may make future investment more dependent on external funding.
Gujarat Themis Biosyn Ltd News
GUJTHEM FAQ
What was Gujarat Themis Biosyn Ltd’s price range in the past 12 months?
Gujarat Themis Biosyn Ltd lowest stock price was ₹225.75 and its highest was ₹479.45 in the past 12 months.
What is Gujarat Themis Biosyn Ltd’s market cap?
Gujarat Themis Biosyn Ltd’s market cap is ₹45.71B.
When is Gujarat Themis Biosyn Ltd’s upcoming earnings report date?
Gujarat Themis Biosyn Ltd’s upcoming earnings report date is Nov 11, 2026 which is in 69 days.
How were Gujarat Themis Biosyn Ltd’s earnings last quarter?
Gujarat Themis Biosyn Ltd released its earnings results on Aug 07, 2026. The company reported ₹1.016 earnings per share for the quarter.
Is Gujarat Themis Biosyn Ltd overvalued?
According to Wall Street analysts Gujarat Themis Biosyn Ltd’s price is currently Overvalued.
Does Gujarat Themis Biosyn Ltd pay dividends?
Gujarat Themis Biosyn Ltd pays a Notavailable dividend of ₹0.67 which represents an annual dividend yield of 0.16%. See more information on Gujarat Themis Biosyn Ltd dividends here
What is Gujarat Themis Biosyn Ltd’s EPS estimate?
Gujarat Themis Biosyn Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gujarat Themis Biosyn Ltd have?
Gujarat Themis Biosyn Ltd has 108,965,260 shares outstanding.
What happened to Gujarat Themis Biosyn Ltd’s price movement after its last earnings report?
Gujarat Themis Biosyn Ltd reported an EPS of ₹1.016 in its last earnings report. Following the earnings report the stock price went down -1.233%.
Which hedge fund is a major shareholder of Gujarat Themis Biosyn Ltd?
Currently, no hedge funds are holding shares in IN:GUJTHEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Ltd. is an Indian company primarily involved in the creation of pharmaceuticals and medicinal chemicals. The firm also supplies bulk drugs via a job work model within India. Its product offerings include important compounds such as Rifamycin-S, an intermediate used in treatments for tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease. Another key product, Rifamycin-O, addresses ailments like traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy. Furthermore, they produce Lovastatin. Established in 1981, the company's operations are based out of Mumbai, India.
Technical Analysis
Gufic Biosciences Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Morepen Laboratories Limited
―
Orchid Pharma Limited
―
Unichem Laboratories Limited
―